Cambridge, MA-based Epizyme, Inc., a biopharmaceutical company founded in 2007 to create innovative drugs for major diseases based on new discoveries emerging from the field of epigenetics, closed a $32m Series B financing led by new investor Bay City Capital (BCC).
BCC was joined by new investors Amgen Ventures and Astellas Venture Management and existing investors MPM Capital and Kleiner Perkins Caufield and Byers (KPCB).
In coincidence with the closing of the funding, Carl Goldfischer, MD, a BCC investment partner and managing director, joins the company’s Board of Directors.
FinSMEs
07/10/2009